The current state of GPCR-based drug discovery to treat metabolic disease.

about

The current state of GPCR-based drug discovery to treat metabolic disease.

Item

http://www.wikidata.org/entity/Q47696468

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

The current state of GPCR-based drug discovery to treat metabolic disease.

@en

The current state of GPCR-based drug discovery to treat metabolic disease.

@nl

type

Item

label

The current state of GPCR-based drug discovery to treat metabolic disease.

@en

The current state of GPCR-based drug discovery to treat metabolic disease.

@nl

prefLabel

The current state of GPCR-based drug discovery to treat metabolic disease.

@en

The current state of GPCR-based drug discovery to treat metabolic disease.

@nl

P1476

The current state of GPCR-based drug discovery to treat metabolic disease

@en

P2093

Kyle W Sloop

http://www.w3.org/2001/XMLSchema#string

Michael A Statnick

http://www.w3.org/2001/XMLSchema#string

Paul J Emmerson

http://www.w3.org/2001/XMLSchema#string

P2860

Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes

Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus

GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

How to improve R&D productivity: the pharmaceutical industry's grand challenge

Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies

Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.

Gut hormone PYY(3-36) physiologically inhibits food intake.

Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men.

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

P304

4060-4071

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BPH.14157

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

175

http://www.w3.org/2001/XMLSchema#string

P50

Francis S Willard

P577

2018-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29394497

http://www.w3.org/2001/XMLSchema#string

P932

6177613

http://www.w3.org/2001/XMLSchema#string